Novo Nordisk (NVO) is seeking up to $830 million in damages from KBP Biosciences, alleging the Singapore-based firm engaged in fraud during the 2023 sale of ocedurenone, a drug that supposedly treated hypertension, according to an Feb. 14 court document made public this week.
A Singapore court has ordered all of the assets of KBP and its founder frozen, according to the ruling.
The ruling stated that the court was "satisfied that Novo has shown that it has a good arguable case against KBP for fraud under New York law, which governs the dispute."
Novo Nordisk bought ocedurenone for up to $1.3 billion in 2023 but announced an impairment loss of about $800 million the following year after poor clinical trial results, Bloomberg reported.
Novo Nordisk and KBP Biosciences did not immediately reply to MT Newswires' request for comment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。